Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Moodys
McKesson
Baxter
Johnson and Johnson

Last Updated: May 25, 2022

XELPROS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Xelpros, and when can generic versions of Xelpros launch?

Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has nineteen patent family members in seventeen countries.

The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xelpros

A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.

  Try it Free

US Patents and Regulatory Information for XELPROS

XELPROS is protected by two US patents.

Patents protecting XELPROS

Ophthalmic composition comprising a prostaglandin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Ophthalmic composition comprising a prostaglandin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm XELPROS latanoprost EMULSION;OPHTHALMIC 206185-001 Sep 12, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sun Pharm XELPROS latanoprost EMULSION;OPHTHALMIC 206185-001 Sep 12, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XELPROS

See the table below for patents covering XELPROS around the world.

Country Patent Number Title Estimated Expiration
Israel 205095 See Plans and Pricing
Japan 5646331 See Plans and Pricing
Brazil PI0818459 See Plans and Pricing
South Korea 101510185 See Plans and Pricing
Australia 2008344909 See Plans and Pricing
European Patent Office 2197449 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XELPROS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0364417 C970039 Netherlands See Plans and Pricing PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
0364417 9690031-1 Sweden See Plans and Pricing PRODUCT NAME: LATANOPROST
0364417 SPC/GB97/014 United Kingdom See Plans and Pricing PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
3461484 C202130024 Spain See Plans and Pricing PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
0364417 97C0111 Belgium See Plans and Pricing PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
0364417 61/1997 Austria See Plans and Pricing PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
Express Scripts
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.